Sort
82,697 grants matching “vaccine development”
Cancer Center Support (Core) Grant
$3,572,644Tyler E Jacks · Massachusetts Institute Of Technology · P30 · FY2019 · CA
Improved Testing for COVID-19 in Skilled Nursing Facilities: IMPACT-C
$3,572,603Vincent Mor · Brown University · U54 · FY2020 · AG
Antigen-specific T-cell Activation, Application to Vaccines for Cancer and AIDS
$3,571,550Jay A Berzofsky · Division Of Clinical Sciences - Nci · ZIA · FY2013 · CA
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components
$3,569,552Sandra D. Comer · New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc · UH3 · FY2023 · DA
Individualized HIV Curative Combination Strategy against Persistent HIV on ART
$3,568,644Luis J. Montaner · Wistar Institute · UM1 · FY2025 · AI
SUPPORT CONTRACT FOR THE NTP INTERAGENCY CENTER/VALIDATION OF ALT METHODS
$3,568,364David Allen · Integrated Laboratory Systems, Llc · N01 · FY2012 · ES
University of Washington/Fred Hutch Center for AIDS Research
$3,565,036Connie L Celum · University Of Washington · P30 · FY2025 · AI
Vaccines for fentanyl and its derivatives: A strategy to reduce illicit use and overdose
$3,564,333Marco Pravetoni · University Of Washington · UH3 · FY2023 · DA
Tissue and organ specific human B cell immunity
$3,563,564Frances E. Lund · University Of Alabama At Birmingham · U19 · FY2019 · AI
Tissue and organ specific human B cell immunity
$3,562,534Frances E. Lund · University Of Alabama At Birmingham · U19 · FY2020 · AI
Immune Responses to Malaria and HIV Infection and Immunization
$3,561,064Kenneth D Stuart · Seattle Children'S Hospital · U19 · FY2020 · AI
Immune Responses to Malaria and HIV Infection and Immunization
$3,561,064Kenneth D Stuart · Seattle Children'S Hospital · U19 · FY2021 · AI
Immune Responses to Malaria and HIV Infection and Immunization
$3,561,064Kenneth D Stuart · Seattle Children'S Hospital · U19 · FY2019 · AI
Multicenter AIDS Cohort Study
$3,561,058Steven M Wolinsky · Northwestern University At Chicago · U01 · FY2018 · AI
Transforming HIV vaccine design with a hybrid technology that leverages features of mRNA and protein nanoparticle platforms
$3,559,750Magnus Adrian Gero Hoffmann · J. David Gladstone Institutes · R01 · FY2025 · AI
Clinical Trials of Biodefense Vaccines (Dengue, West Nile Virus, TBEV)
$3,559,544Brian Murphy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
The UNC/Emory Center for Innovative Technology (iTech) across the prevention and care continuum
$3,558,967Lisa B Hightow-Weidman · Univ Of North Carolina Chapel Hill · U19 · FY2017 · HD
Tissue and organ specific human B cell immunity
$3,558,962Frances E. Lund · University Of Alabama At Birmingham · U19 · FY2021 · AI
Tissue and organ specific human B cell immunity
$3,556,205Frances E. Lund · University Of Alabama At Birmingham · U19 · FY2022 · AI
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS
$3,554,482Daniel Ernest Ford · Johns Hopkins University · UL1 · FY2009 · RR
Assessing the effects of oral pre-exposure prophylaxis on pharmacokinetics of monoclonal and vaccine-induced antibodies among women vulnerable to HIV-1
$3,554,273Yunda Huang · Fred Hutchinson Cancer Center · R01 · FY2025 · AI
Tissue and organ specific human B cell immunity
$3,552,993Frances E. Lund · University Of Alabama At Birmingham · U19 · FY2023 · AI
Optimal T-cell support for HIV neutralizing antibody induction to fusion peptide-inclusive regimens (Opti-FliP)
$3,552,620Dennis J Hartigan-O'Connor · University Of California At Davis · P01 · FY2025 · AI
Viral Hemorrhagic Fevers: Disease Modeling and Transmission
$3,552,426Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Multicenter AIDS Cohort Study
$3,552,111Steven M Wolinsky · Northwestern University At Chicago · U01 · FY2015 · AI